Scientific Advisor
Nucleus CapitalCheck size: Up to €1M initially, as published by Nucleus Capital.
Dr. Mazen Rizk supports Nucleus Capital, whose published strategy is: Write first checks into European and US founders applying programmable biology and deep technology to food, materials and neo-industrial systems.
Founders whose work fits Nucleus Capital's stated focus and who can show a large problem, differentiated insight, credible execution and evidence appropriate to the stage.
Opportunities outside Nucleus Capital's published stage, geography or sector focus are less aligned; no broader exclusion is inferred where the firm does not publish one.
Show founder-market fit, the problem and product, technical or commercial differentiation, traction, market scale, financing plan and why Nucleus Capital's stated focus is a match.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Dr. Mazen Rizk is listed by Nucleus Capital as Scientific Advisor on the firm's current official roster. No additional employment history is inferred where the official roster does not publish it.